Skip to main content
COAG logo

COAG · Hemab Therapeutics Holdings, Inc.

Track COAG — free
$38.71 -0.45 (-1.14%)
Market Cap
$1.83B
Shares
46.73M
Volume · Nov 19 43.99K Avg daily vol (3M) 496.12K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$39.15 Open$39.30 Day$38.61–40.28 Available close range$24.98–54.94 Avg vol 30d475K Short int3.3M · 7.1% of shares · 7.3d Short vol87% Last earningsNov 10, 2026 DataMay 2026–Nov 2026 Filing10-Q · Nov 10

The closing range uses available history since May 1, 2026; less than a full year is stored.

Latest documents

2026
Nov 17
Investor event
Glansman phase 3 study design set; cash runway into 2029

Hemab's CEO said the phase 3 Glansman study uses a single-arm design with approximately 75 patients. The company has more than $400 million in cash, with runway well into 2029.

4 source passages
We have a molecule, Cytasimac, that is now in phase 3 pivotal trials in Glansman's thrombustenia. And the strongest way of doing that is a single-arm trial. Yeah, so it's approximately 75 patients. Yeah, there is nicely more than $400 million in the bank, runway well into 2029. Open the document at this passage
Nov 10
Quarterly report 10-Q FY2026 Q3, ended Sep 30
SOLARA Phase 3 initiated as loss widens

Hemab Therapeutics Holdings, Inc. initiated SOLARA Phase 3 of sutacimig in November 2026. Its nine-month net loss was $74.1 million, while cash and marketable securities totaled $430.2 million as of September 30, 2026, funding operations into 2029.

Net loss $27.3M Diluted EPS -$0.58
Read from the MD&A section
4 source passages
On March 30, 2026, we completed a corporate reorganization pursuant to which the shareholders of Hemab ApS exchanged their shares in Hemab ApS for the same number, class and series of newly issued shares, on a one to one basis, in the newly incorporated Delaware company, Hemab Therapeutics Holdings, Inc. and, as a result, Hemab ApS became a wholly owned subsidiary of Hemab Therapeutics Holdings, Inc. In November 2026, we initiated SOLARA, a pivotal, open-label, single-arm, multicenter Phase 3 clinical trial of once-weekly subcutaneous sutacimig for Glanzmann thrombasthenia, which is expected to enroll approximately 75 participants aged 12 to 70. Our net losses were $74.1 million and $44.6 million for the nine months ended September 30, 2026 and 2025, respectively. As of September 30, 2026, we had cash, cash equivalents and marketable securities of $430.2 million. We believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements into 2029. Open the document at this passage
Nov 10
Earnings call
Pivotal trial launched with cash runway into 2029

HEMAP initiated SOLARA, its first Phase III trial, and reported $430.2 million in cash, cash equivalents and marketable securities as of September 30. The company expects cash to fund operations into 2029.

4 source passages
With Solara, HEMAP has now begun its transition to a late-stage clinical company. And we've now initiated SOLARA, our pivotal Phase III trial of Cytasomec in Glantzman's Frombasthenia. Cash, cash equivalents, and marketable securities were $430.2 million as of September 30 We continue to expect our cash to fund operations into 2029. Open the document at this passage
Nov 10
Current report 8-K
SOLARA Phase 3 trial begins in Glanzmann thrombasthenia

Hemab Therapeutics began SOLARA, a Phase 3 trial of subcutaneous prophylactic sutacimig in Glanzmann thrombasthenia. It reported $430.2 million in cash, cash equivalents, and marketable securities as of September 30, 2026, and a $27.3 million quarterly net loss.

Financial results
4 source passages
“We are excited to have started our Phase 3 study in Glanzmann thrombasthenia, transitioning Hemab to a biotech company with clinical stage programs ranging from Phase 1 to Phase 3 across our portfolio,” In November, the Company initiated SOLARA, an open-label, single-arm, multicenter Phase 3 trial enrolling approximately 75 participants aged 12 to 70 years with GT who have had at least four treated bleeding events in the 12 months before screening. Cash, cash equivalents, and marketable securities totaled $430.2 million as of September 30, 2026, compared to $457.5 million as of June 30, 2026. Net loss was $27.3 million, or $0.58 per share, for the three months ended September 30, 2026, compared to a net loss of $17.1 million, or $18.04 per share, for the three months ended September 30, 2025. Open the document at this passage
Sep 24
Current report 8-K
Director or officer change, or executive pay

Hemab Therapeutics Holdings, Inc. elected Keli Walbert as a Class I director and Audit Committee member, effective immediately. Her term expires at the 2027 annual meeting, and she will receive an option to purchase 36,000 shares vesting through the third anniversary.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$430.24M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+4,837.8%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
7.1%
Latest settlement · 7.3 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 10, 2026
Q3 FY26

TL;DR. Hemab initiated SOLARA, the first pivotal trial of a subcutaneous prophylactic treatment in Glanzmann thrombasthenia, reported positive initial clinical data for sutacimig in Factor VII deficiency and positive HMB-002 clinical data, and expects cash to fund operations into 2029. Concerns include rising quarterly expenses and losses, lower cash, Grade 2 thromboembolic events, and regulatory risks surrounding SOLARA’s single-arm design.

Bullish
  • + SOLARA is the first pivotal trial of a subcutaneous prophylactic treatment in Glanzmann thrombasthenia.
  • + Initial Factor VII deficiency data showed more than 50% shortening of prothrombin time in both participants and sustained approximately 5x accumulation of endogenous FVII(a) in the participant with PK/PD data available to date.
  • + VELORA Pioneer data demonstrated proof of mechanism, including a ≥2.4-fold peak increase in VWF and FVIII and durability supporting potential monthly dosing.
  • + Eight of nine evaluable HMB-002 patients had zero treated bleeds during the 28 days after dosing, with mean ATBR of 1.6 versus 20.1 before treatment.
  • + Hemab dosed the first participant in the Phase 1 trial of HMB-003 for heavy menstrual bleeding.
  • + Hemab expects its current cash resources to fund operating expenses and capital expenditure requirements into 2029.
Bearish
  • − Research and development expense increased to $24.6 million in Q3 2026 from $14.6 million in the prior-year quarter.
  • − General and administrative expense increased to $5.1 million in Q3 2026 from $2.5 million in the prior-year quarter.
  • − Net loss increased to $27.3 million in Q3 2026 from $17.1 million in the prior-year quarter.
  • − Cash, cash equivalents, and marketable securities declined to $430.2 million at September 30, 2026 from $457.5 million at June 30, 2026.
  • − Three participants in higher-exposure cohorts or with multiple risk factors experienced Grade 2 thromboembolic events.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Very Strong Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 50-day avg +7%
above
RSI (14) 50
neutral
MACD trend Negative
52-week position 47%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +11%
trailing
6-month return +37%
trailing
Relative strength +41%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+59% holders QoQ · +41 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
7.07% of shares out · ▲ +4.6% MoM · 7.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
89 holders — 13F breadth
Squeeze score 71
high risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 87%
annualized · 1-yr
Max drawdown −48%
past year
ATR 8.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 50-day avg
+7% Bullish
RSI (14)
50 Neutral
MACD trend
Negative Bearish
52-week position
47% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+59% holders QoQ · +41 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
7.07% of shares out · ▲ +4.6% MoM · 7.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
89 holders — 13F breadth
Price context
position in its available closing range
Range low $25 Now $39 · 47% Range high $55
vs 50-day avg +7%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash, cash equivalents, and marketable securities $430.2M as of September 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
COAG
Hemab Therapeutics Holdings, Inc.
this stock
$1.83B — — — 7.1%
VRTX
Vertex Pharmaceuticals Inc
$136.01B +18.3% +46.2% 34.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$97.81B +22.5% +20.8% 20.9 2.1%
MRNA
Moderna, Inc.
$79.63B +567.3% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.15B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
89
% held
85.3%
Net QoQ
+3.6M sh
Top holder
RA CAPITAL MANAGEMENT, L.…
Held Float
View
Held by Funds
Fund positions
67
View
Short & Settlement
Short Interest Rising
Shares short
3.3M
Days to cover
7.3d
Change
+144.2K sh
View
Short Volume
Short vol %
87%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
102.6K
Value
$4.0M
As of
Oct 29, 2026
View
Off-Exchange
Off-exchange %
50.8%
Week of
Oct 12, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 17, 2026
This year
15

Hemab's CEO said the phase 3 Glansman study uses a single-arm design with approximately 75 patients. The company has more than $400 million in cash, with runway well into 2029.

View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 1, 2026
Last webcast
Nov 17, 2026
View
Investor Relations
Latest news
Hemab Therapeutics to Participate…
Published
Nov 11, 2026
Upcoming events
2
View

Performance

5D 20D 120D MTD YTD
COAG -0.5% +10.8% +37.4% -5.6% —
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY +3.4% +16.3% +40.8% -2.2% —
Key facts CIK 2114044 CUSIP 423494103 13F (30d) 89 filings 88 filers Visit website Investor relations